Form 4: Lucid Diagnostics Director Acquires Restricted Stock

Director Dennis Matheis acquires 112,800 shares of restricted stock in Lucid Diagnostics, while disposing of 0 shares.

Summary

• On February 20, 2025, Dennis Matheis, a director of Lucid Diagnostics Inc. [LUCD], acquired 112,800 shares of Common Stock.
• The acquisition was in the form of restricted stock granted under the Issuer's 2018 Equity Plan.
• The restricted stock has a single vesting date of May 20, 2028, and is subject to forfeiture if the service period is not completed.
• Following the transaction, Matheis directly owns 162,725 shares of Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's acquisition of restricted stock, indicating confidence in the company's future. However, it's a routine transaction.

Positives

• The acquisition of restricted stock by a director signals confidence in the company's future.

Risks

• The restricted stock is subject to forfeiture if the service period is not completed, which could impact the director's long-term commitment.

Future Outlook

The document does not contain specific forward-looking statements, but the grant of restricted stock suggests a long-term incentive for the director.

Industry Context

Acquisition of company stock by a director is generally viewed positively, as it aligns the director's interests with those of the shareholders.

Stakeholder Impact

• The acquisition of restricted stock by a director can positively influence shareholder sentiment.

Key Dates

Keywords

Lucid Diagnostics, Director, Dennis Matheis, Restricted Stock, Equity Plan, Beneficial Ownership, Form 4